About AGTCAGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC's lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC is also pursuing pre-clinical development of treatments for wet AMD using the company's experience in vector design and ophthalmology to expand into disease indications with larger markets.
|ETF Ticker||ETF Name||Net Assets||Net Assets Raw||# Holdings||# Holdings Raw||Weight||Weight Raw||Market Value||Market Value Raw|
|Vanguard Total Stock Market ETF||119.5 B||1.195E+11||3,575||3575||0.0%||0||247 K||246555|
|Vanguard Extended Market ETF||7.3 B||7.3E+09||3,266||3266||0.0%||1E-05||82 K||82244|
|iShares Core S&P Total U.S. Stock Market ETF||22.0 B||2.20343E+10||3,546||3546||0.0%||0||21 K||20519|
|iShares Microcap ETF||800.2 M||8.00224E+08||1,388||1388||0.02%||0.0002||119 K||119374|